All News

January 18 2023

Set Up for Success - Coordinating RECIST 1.1: A Community Hospital Perspective

Read more

January 18 2023

#FORTEStudy Workshop

Read more

January 18 2023

NRG Innovations Continue in Cancer Care Delivery Research

Read more

January 18 2023

Adding Atezolizumab to Cisplatin and Radiotherapy for Node-Positive Locally Advanced Cervical Cancer (NRG-GY017)

Read more

January 18 2023

A Message from the NRG Oncology Research Strategy Committee Chairs: 2022: The Year in Review

Read more

January 18 2023

A Message from the NRG Oncology Group Chairs: 2022 in Review and a Look Ahead

Read more

December 19 2022

NRG Oncology Holiday Closures for 2022

Read more

December 12 2022

NRG Meeting PSC Information

Read more

December 12 2022

NRG-CC005/FORTE Site Implementation Guide: Part 1

Read more

December 12 2022

Julian Hong, M.D., M.S.: Steward of Cancer Care Delivery Research and Innovation

Read more

December 12 2022

NRG Oncology Announces Leadership of New Diversity, Equity, and Inclusion Committee, New Vice Chair for Ancillary Projects Committee

Read more

November 09 2022

Protocol Support Committee Column: NRG Best Practice Tool

Read more

November 09 2022

Dr. Jong H. Jeong Joins NRG Oncology SDMC

Read more

November 09 2022

#FORTEStudy is on YouTube!

Read more

November 09 2022

Assessing SBRT to the Primary Tumor Followed by Conventional Radiation Therapy with Concurrent Chemotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer (NRG-LU008)

Read more

November 09 2022

Assessing the Addition of IMPRINT to Surgery and Systemic Therapy for Malignant Pleural Mesothelioma (NRG-LU006)

Read more

November 03 2022

NRG Oncology Patient Advocate Committee - Call for Candidates

Read more

October 24 2022

Multi-Modal Artificial Intelligence Models Offer a More Accurate Prognostication Method for Intermediate- to High-Risk Localized Prostate Cancer than Current NCCN Standard

Read more

October 24 2022

NRG Oncology Trial NRG-HN004 Shows Addition of Durvalumab to Radiation Does Not Improve Outcomes over Cetuximab for Head & Neck Squamous Cell Carcinoma Patients with a Contraindication to Cisplatin, Highlights Need for Further Research

Read more

October 24 2022

Three Week Hypo-fractionated Whole Breast Irradiation (WBI) with Concurrent Boost is not Inferior to Conventional WBI with a Sequential Boost Following Lumpectomy for Patients with High-Risk, Early-Stage Breast Cancer

Read more

October 24 2022

The Addition of Stereotactic Body Radiation Therapy (SBRT) to Sorafenib in Patients with Advanced Hepatocellular Carcinoma Improves Overall Survival

Read more

October 12 2022

The Protocol Support Committee (PSC) Wants You!

Read more

October 12 2022

#FORTEStudy in Chicago!

Read more

October 12 2022

Comparing Docetaxel and Trastuzumab to Ado-Trastuzumab Emtansine for HER2-positive Salivary Gland Cancer (NRG-HN010)

Read more

October 12 2022

Assessing the Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer (NRG-CC010)

Read more

October 12 2022

NRG-BR008 (“HERO”): A Phase III Randomized Trial Seeking to Optimize Use of Radiotherapy in Patients with Early-Stage, Low Risk, HER2-Positive Breast Cancer

Read more

October 12 2022

NRG-BR007 (“DEBRA”): A Phase III Clinical Trial Evaluating the De-escalation of Breast Radiation for a More Conservative Treatment of Patients With Low-Risk, Hormone-Sensitive, Node-Negative Breast Cancer

Read more

October 06 2022

NRG Oncology Appoints Chair & Vice Chair of Radiation Oncology Committee

Read more

September 26 2022

Foundation Accrual Credit for NRG Membership Requirements Announcement

Read more

September 21 2022

Intensity Modulated Radiotherapy Improved Patient-Reported Outcomes on NRG Oncology Clinical Trial

Read more

September 15 2022

In Memoriam: James Lloyd Hoehn, MD, FACS

Read more

September 15 2022

Protocol Committee Support (PSC) Column: No Surprises Billing Act 2022

Read more

September 15 2022

NRG Health Equity Fellowship Call for Applications

Read more

September 15 2022

Comparing the Addition of Radiation before or After Surgery for Patients with Brain Metastases (NRG-BN012)

Read more

September 15 2022

Comparing Every Three Week Versus Weekly Cisplatin with Radiotherapy for Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

Read more

September 15 2022

NRG-GU011 (“NRG PROMETHEAN”) study of SABR with or without relugolix for PET-recurrent oligometastatic prostate cancer

Read more

September 15 2022

NRG-GU009 ( “PREDICT-RT”) Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation

Read more

September 15 2022

Testing the addition of trastuzumab or trastuzumab/pertuzumab to the usual chemotherapy for HER2 positive uterine serous or carcinosarcoma (NRG-GY026)

Read more

September 12 2022

NRG Oncology accepting applications for the position of Vice Chair, Ancillary Projects Committee

Read more

August 18 2022

NRG Oncology and The GOG Foundation Honor the Life of Mary "Dicey" Scroggins

Read more

August 12 2022

Summer Meeting 2022 Protocol Support Committee (PSC) Wrap Up

Read more

August 12 2022

FORTE Study Updates: Natural Language Processing Update

Read more

August 05 2022

NRG Oncology accepting applications for the position of Vice Chair, Radiation Oncology Committee

Read more

July 29 2022

NRG Oncology Trial Aimed to Improve Prostate Cancer Survivor Care Planning Reaches Accrual Goal

Read more

July 27 2022

Oncology Tube Conducts Interviews on NRG Oncology Research Presented During the 2022 ASCO Annual Meeting: NRG-HN002 and NRG-GI008

Read more

July 26 2022

NRG Oncology NCORP Trial of Hippocampal Avoidance for Small Cell Lung Cancer Patients Receiving Prophylactic Cranial Irradiation Reaches Accrual Goal

Read more

July 19 2022

NRG Oncology Appoints Several New Committee Chairs & Vice Chairs

Read more

July 13 2022

Adding Stereotactic Radiation Therapy to Immune Therapy for Patients with Advanced Renal Cell Cancer (NRG-GU012, The “SAMURAI” Study)

Read more

July 13 2022

IACRN: International Association of Clinical Research Nurses

Read more

July 13 2022

NRG NCORP Selects CCDR Pilot Project Awardee

Read more

July 13 2022

Join FORTE at the NRG Oncology Semiannual Meeting!

Read more

July 12 2022

NRG Oncology Accepting Applications for Radiation Oncology Committee Chair Position

Read more

July 08 2022

NRG Oncology Study of Atezolizumab and Chemoradiation for Patients with Limited-Stage Small Cell Lung Cancer Completes Accrual

Read more

June 29 2022

PSA-Based Endpoints Should Not Be Used as Surrogate Endpoints for Overall Survival in Men with Recurrent Prostate Cancer at this Time

Read more

June 28 2022

Joint Final Report of Phase III trials Demonstrate Positive Outcomes from Combination of PCV Chemotherapy and RT in Patients with Anaplastic Oligodendroglial Tumors

Read more

June 27 2022

Additional Taxane Maintenance Therapy Does Not Successfully Improve Overall Survival for Women with Advanced Ovarian, Peritoneal, and Tubal Cancers

Read more

June 08 2022

The Vision of Remote Auditing and Monitoring

Read more

June 08 2022

NRG-CC005 (FORTE) Breaking News! Welcome to the FORTE Education and Communication Specialist

Read more

May 12 2022

NRG Oncology NCORP Accepting Applications for NRG Meeting Travel Awards: Deadline May 26, 2022

Read more

May 11 2022

Preparing for the NRG Quality Assurance Audit

Read more

May 11 2022

FORTE STUDY UPDATE: NRG-CC005/FORTE Trial Communications

Read more

May 11 2022

A Randomized Phase II Trial of Immunotherapy with Dual Immune Checkpoint Inhibitors Compared to Anti-PD1 Monotherapy in Patients with Deficient Mismatch Repair System Recurrent Endometrial Carcinoma (NRG-GY025)

Read more

May 11 2022

A Study Champion Perspective: Christina Henson, MD

Read more

May 11 2022

Upcoming Trial Highlight: Studying Stereotactic Radiosurgery Before Versus After Surgery for Patients with Resectable Brain Metastases (NRG-BN012)

Read more

May 11 2022

NRG-BN011 Seeks to Improve Treatment Outcomes in a Substantial Subset of Glioblastoma Patients with Dual Alkylating Therapy

Read more

May 11 2022

A Safety Run-in and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma (NRG-BN010)

Read more

May 09 2022

NRG Oncology Study of Photon Versus Proton Therapy for Patients with Newly Diagnosed Glioblastoma Completes Accrual

Read more

May 09 2022

NRG Oncology Board of Directors Member, Dr. Priya Rastogi named NSABP Foundation CEO

Read more

April 29 2022

NRG Oncology Executive Director is Stepping Down from the Position

Read more

April 29 2022

NRG NCORP is Soliciting PILOT Projects Focused on Biospecimens and Clinical Trial Data: Breast Cancer Prevention Studies

Read more

April 29 2022

DEADLINE APRIL 29TH: NRG Oncology seeks to fill the position of Chair, NRG Oncology Surgical Oncology Committee

Read more

April 19 2022

West Valley Ovarian Cancer Alliance Gifts Generous Donation to the NRG Oncology Under-Represented Minority Investigator Program

Read more

April 13 2022

DEADLINE EXTENDED: NRG Oncology seeks to fill the position of Chair, NRG Oncology Immunotherapy Subcommittee

Read more

April 12 2022

FORTE STUDY UPDATE: NRG-CC005 (The FORTE Study)

Read more

April 12 2022

Testing ctDNA as a Biomarker for Adjuvant Therapy Intensity in Stage 3 Colon Cancer (NRG-GI008, The “CIRCULATE-US” Study)

Read more

April 12 2022

April is National Cancer Control Month: NRG Protocol Support Committee Column

Read more

April 12 2022

Exploring Options to Potentially Improve Treatment and Quality of Life for Patients in Two Head and Neck Cancer Trials

Read more

April 11 2022

NRG Oncology Announces New Veterans Affairs and Military Treatment Facility Subcommittee, Appoints Subcommittee Chairs

Read more

April 08 2022

NRG Oncology seeks applications for Chair of the NRG Early Career New Investigators Committee

Read more

March 24 2022

Webinar: Implementation Science for Digital Health

Read more

March 18 2022

NRG Oncology Trial Indicates Using Atezolizumab with Chemoradiation is Safe and Demonstrates Signs of Immune Activation in Women with Cervical Cancer

Read more

March 18 2022

HRR Mutational Status Prognostic of Survival Outcomes in Biomarker Analysis of NRG Oncology Trial for Women with Recurrent Platinum-Sensitive Ovarian Cancer

Read more

March 16 2022

OlympiA Trial (NSABP B-55): Olaparib as adjuvant treatment reduces risk of death by 32% in patients with germline BRCA mutations and high-risk early breast cancer

Read more

March 10 2022

NRG Oncology seeks to fill the position of Co-Chair, Patient Centered Outcomes Research Committee

Read more

March 08 2022

NRG Oncology PSC 2022 Winter Meeting Wrap Up

Read more

March 08 2022

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces - Rectal/Anal Cancers

Read more

March 08 2022

FORTE Study Update - March NRG Newsletter

Read more

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI005

Read more

March 08 2022

Coming Attractions or Recent Additions in NRG Colorectal Cancer Research: NRG-GI008

Read more

March 08 2022

The NRG-GI004/SWOG1610, the COMMIT Study, may further improve outcomes in Metastatic Colorectal Cancer with deficiency of DNA repair (dMMR/MSI- H)

Read more

March 08 2022

Project Team Member Application - CBX-12

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Care Delivery Research (CCDR) Priorities

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Health Disparities Research (HDR) Priorities

Read more

February 18 2022

NRG NCORP Solicits PILOT Projects for NRG NCORP Cancer Prevention Control (CPC) Priorities

Read more

February 15 2022

2022 Symposium & Workshop: Precision Medicine Applications in Radiation Oncology

Read more

February 11 2022

The Scientific Session - February 2022

Read more

February 09 2022

NRG Oncology Announces First Participant Enrolled on FORTE NRG-CC005

Read more

February 08 2022

Dr. Miller Re-elected as Biostatistician for the NCI Uterine Task Force

Read more

February 08 2022

RECIST 1.1 Criteria Toolkit: A Resource for Success in Clinical Trials with Solid Tumor Evaluation Requirements

Read more

February 08 2022

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Read more

February 08 2022

FORTE Study Updates (Feb 2022 Newsletter)

Read more

February 03 2022

NRG Oncology Trial Results Indicate Trametinib Should Represent the New Standard of Care for Women with Recurrent Low-Grade Serous Ovarian Cancer

Read more

January 21 2022

Trastuzumab with Chemoradiation and Surgery Does Not Improve Outcomes for Esophageal Cancer Patients, Trial Highlights Future Research Opportunities

Read more

January 12 2022

It’s All in the DETAILS!

Read more

January 12 2022

Moving Research Forward through Legislative Advocacy

Read more

January 12 2022

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009, the “PREDICT-RT” Trial)

Read more

January 12 2022

Phase 2 Double-Blinded Trial Combining Oligometastatic Radiotherapy with Androgen Deprivation Therapy (NRG-GU011)

Read more

January 12 2022

NRG-CC005 “FORTE” Amendment #3 is Now Active

Read more

January 12 2022

A Message from the Chairs of NRG Oncology’s Research Strategy Committee, 2021: The Year in Review

Read more

January 12 2022

Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer – Outcomes Presented Soon! (NRG-GY017)

Read more

January 11 2022

NRG Oncology Trial Data Concludes Paclitaxel and Carboplatin Should be Considered the Standard of Care as First-line Treatment for Women with Uterine Carcinosarcoma

Read more

December 20 2021

Barbara Good, PhD, to Retire from NRG Oncology and the NSABP Foundation

Read more

December 10 2021

Bupropion Does Not Improve Sexual Desire for Female Cancer Survivors on NRG Oncology Clinical Study

Read more

December 09 2021

Get to Know the Protocol Support Committee (PSC)

Read more

December 09 2021

Why Should We Participate in NRG-CC005/FORTE?

Read more

December 09 2021

Phase 3 Trial Combining Two Alkylating Agents with Radiotherapy for Newly Diagnosed Glioblastoma (NRG-BN011)

Read more

December 09 2021

Phase 3, Node-Positive Prostate Cancer Trial Reactivates Following Change to Experimental Treatment Arm (NRG-GU008, the INNOVATE trial)

Read more

December 06 2021

Winter 2021 Holiday Hours

Read more

December 01 2021

NRG Oncology Non-Small Cell Lung Cancer Trial Completed Accrual to Phase 2, Undergoing Data Analysis to Determine Reopening for Phase 3

Read more

December 01 2021

Annual Call for NRG Oncology Administrative Committee Member Applications

Read more

November 23 2021

Machtay Young Investigator Travel Award (Winter 2022 NRG Meeting)

Read more

November 16 2021

NRG Oncology Seeks Applicants for the Veterans Affairs/Military Treatment Facility Subcommittee Chair Position

Read more

November 11 2021

Mei-Yin C. Polley, PhD Re-elected to Serve as the Biostatistician on the NCI Head & Neck Steering Committee

Read more

November 11 2021

Background: National Coverage Analysis

Read more

November 11 2021

The NRG-CC005 (FORTE) Trial has Activated!

Read more

November 11 2021

Comparing High- and Low-Dose Cisplatin for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (NRG-HN009)

Read more

November 11 2021

New Prostate Cancer Study Testing Higher-intensity Treatment for Patients with Higher Gene Risk Scores and Lower-intensity Treatment for Patients with Lower Gene Risk Scores (NRG-GU010, the GUIDANCE trial)

Read more

November 11 2021

The University of Michigan T32 in Cancer Care Delivery Accepts First Cohort of Pre- and Post- Doctoral Scholars

Read more

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

Read more

November 11 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

Read more

November 11 2021

Combining Radiotherapy and Immunotherapy in Patients with Extensive Stage Small Cell Lung Cancer (NRG-LU007, “the RAPTOR Trial”)

Read more

October 25 2021

Hypofractionated Post-Operative Prostate Bed Radiotherapy Does Not Increase Patient-Reported Toxicity for Men with Prostate Cancer

Read more

October 25 2021

Total Androgen Suppression with Dose-Escalated Radiotherapy Does Not Improve Overall Survival in Men with Intermediate-Risk Prostate Cancer: Results Highlight Need for Biomarker Studies

Read more

October 14 2021

HEAL Initiative: Advancing Health Equity in Pain Management - NOTIFY NRG BY 10/31/21

Read more

October 12 2021

Amendment to address accrual barriers for NRG-BR004 is activated

Read more

October 12 2021

Remote Audits – What is working and what is still missing

Read more

October 12 2021

Former Gynecologic Oncology Group Co-Chair, Dr. Franco Muggia, dies at 85

Read more

October 12 2021

NCI-Sponsored Trials Have Added 14-Million Years of Life for Cancer Patients

Read more

October 12 2021

Congratulations to the NRG Oncology NCORP Members Assigned to NCI Steering Committees

Read more

October 12 2021

Stewart Anderson retires from University of Pittsburgh

Read more

October 12 2021

Jim Dignam Receives the SPAIG Award

Read more

October 12 2021

Assessing the Maximum-Tolerated Dose of AMG 232 (KRT-232) with Concurrent Radiotherapy in the Treatment of Soft Tissue Sarcoma with Wild-Type P53 Gene (NRG-DT001)

Read more

October 12 2021

Congratulations to the NRG Oncology Members Assigned to NCI Gastrointestinal Task Forces

Read more

October 07 2021

NSABP and RTOG Foundations Join GOG Foundation in Funding of the NRG Oncology Health Equity New Investigator Mentor Program

Read more

October 06 2021

NRG Oncology Launches FORTE, a Colorectal Cancer Prevention Clinical Trial

Read more

September 27 2021

Breast Radiation following Lumpectomy Confirmed to Reduce Incidence of IBR for “Good Risk” DCIS

Read more

September 14 2021

Getting Started with Radiation Therapy (RT) Credentialing (September 2021 Newsletter)

Read more

September 14 2021

NRG-CC005 (FORTE): Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps (September 2021 Newsletter)

Read more

September 14 2021

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority (URM) Scholars (September 2021 Newsletter)

Read more

September 14 2021

OvCa Survivors and Thrivers Make Remarkable Strides in Research (Sept 2021 Newsletter)

Read more

September 14 2021

Highlighting NRG Gynecologic Studies: Gynecologic Cancer Awareness Month (Sept 2021 Newsletter)

Read more

August 27 2021

NRG Oncology Appoints Dr. Sue Yom as New Head and Neck Cancer Committee Chair

Read more

August 24 2021

Survival Benefits Not Seen with Addition of Metformin to Concurrent Chemoradiation in Patients with Locally Advanced Non-Small Cell Lung Cancer

Read more

August 13 2021

NRG Oncology Limited-Stage Small Cell Lung Cancer Trial Participant Interviewed on his Journey

Read more

August 13 2021

Opinion: Adoption of Clinical Research Competencies can Set the Stage for Research Success

Read more

August 13 2021

Assessing the Maximum-Tolerated Dose and the Efficacy of Tocilizumab and Atezolizumab in the Treatment of Recurrent Glioblastoma (NRG-BN010)

Read more

August 13 2021

Testing Durvalumab, Olaparib, and Cediranib in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer (NRG-GY023)

Read more

August 13 2021

NRG Oncology Director of Administration, Meetings, and Exhibits, Denise Mackey, Retires After 38 Years

Read more

August 13 2021

Outstanding NRG Oncology Researcher to Receive 2021 PA Breast Cancer Coalition Potamkin Prize

Read more

August 13 2021

NRG Oncology Board of Directors Member, Dr. Jeff Michalski, Named ASTRO President-elect

Read more

July 22 2021

NRG Oncology Plenary Session with Keynote Speaker Dr. Philip E. Castle

Read more

July 13 2021

Pathology and Biospecimen Tips for Success

Read more

June 28 2021

Quynh Le, MD Appointed as an NRG Oncology Group Chair

We are pleased to announce that Quynh-Thu Le, MD, from Stanford University, will serve as one of our three Group Chairs effective July 1, 2021. Read more

June 16 2021

Navigating the Virtual NRG Oncology Group Meeting

Read more

June 16 2021

NRG Oncology GI Committee members appointees to NCI Task Forces

Read more

June 16 2021

Investigating Deintensification of Head and Neck Radiation within NRG Oncology

Read more

June 16 2021

FORTE Coming Soon!

Five- or Ten-Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps Read more

June 16 2021

Recently Activated! NRG-BR007: The DEBRA Trial

Testing Hormonal Therapy Following Lumpectomy without Radiotherapy for Patients with Low-Risk, Early-Stage Breast Cancer (NRG-BR007: The DEBRA Trial) Read more

June 03 2021

OlympiA study results to be presented at 2021 ASCO Annual Meeting

Read more

May 12 2021

Performance Status Measures - A Little History

Read more

April 22 2021

NRG Oncology Study Shows Safety of Using Stereotactic Body Radiotherapy to Treat Multiple Metastases

Read more

April 14 2021

Esophageal Cancer Awareness Month

Read more

April 14 2021

Head and Neck Cancer Awareness Month

Read more

April 14 2021

Acupuncture in Oncology

Read more

March 09 2021

The Significance of Checkpoint Inhibitors and MMR/MSI Testing in Metastatic Colorectal Cancer (NRG-GI004/SWOG1610, the COMMIT Study)

Read more

March 09 2021

Implementing Remote Consenting at the University of Hawaii Cancer Center, A Minority/Underserved NCORP Site

Read more

March 09 2021

Comparing Hippocampal-Avoidant Whole Brain Radiotherapy to Stereotactic Radiosurgery for Patients with 10 or Fewer Brain Metastases from Small Cell Lung Cancer (NRG-CC009)

Read more

March 09 2021

NRG Oncology Board of Directors Appoints New At-Large Director

Read more

February 26 2021

NRG NCORP Solicits PILOT Projects for Applications: Biospecimens & Clinical Trial Data from Breast Cancer Prevention Studies

Read more

February 23 2021

NRG Cancer Prevention Committee Seeks Applications for Chair of Committee

Read more

February 19 2021

NSABP B-55/BIG 6-13 / OlympiA trial crossed superiority boundary for invasive disease-free survival vs. placebo at planned interim analysis

Read more

February 19 2021

NRG Oncology NCORP solicits PILOT projects addressing NRG NCORP Health Disparities (HDC) Research priorities

Read more

February 19 2021

NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities

Read more

February 19 2021

NRG Oncology NCORP solicits PILOT projects addressing NRG NCORP Cancer Care Delivery Research (CCDR) priorities

Read more

February 18 2021

NRG Oncology’s Practice Changing Study on HA-WBRT plus Memantine Was Among Journal of Clinical Oncology’s Top 5 Downloads in 2020

Read more

February 12 2021

The First Lady of the United States and NCI Leadership Highlight the Importance of NCORP on World Cancer Day

Read more

February 11 2021

Recipe for Success for Quality of Life Questionnaire Study Compliance

Read more

February 11 2021

NRG-CC008 Trial Now Open - February 2021 Newsletter

Read more

February 11 2021

National Cancer Prevention Month - February 2021 Newsletter

Read more

February 02 2021

NRG Oncology Appoints New Committee Chairs for Pathology and Health Disparities Research

Read more

January 29 2021

The General Session at the NRG Winter 2021 Virtual Meeting

Read more

January 29 2021

NRG NCORP Townhall at the NRG Winter 2021 Virtual Meeting

Read more

January 29 2021

Reduced-Dose Radiation with Cisplatin Improves Outcomes for HPV-associated Oropharyngeal Carcinoma Patients on NRG Oncology Study, Justifies Phase III Trial

Read more

January 29 2021

NRG Oncology Trial Results Show Safety of Adaptive Radiotherapy in Non-Small Cell Lung Cancer Patients, Open Paths to Future Prospective Studies

Read more

January 28 2021

The NRG New Investigator Sessions at the NRG Winter 2021 Virtual Meeting

Read more

January 20 2021

NRG Oncology Health Equity New Investigator Mentor Program for Underrepresented Minority Scholars

Read more

January 19 2021

A Message from Drs. Norman Wolmark and Robert Mannel

Read more

January 16 2021

NRG Oncology Study Determines Total Neoadjuvant Therapy with Pembrolizumab and Chemoradiotherapy is Safe, but May Not be Beneficial for Patients with Locally-Advanced Rectal Cancer

Read more

January 12 2021

Keeping a Positive Attitude as a Cancer Research Nurse, Through a Global Pandemic

Read more

January 12 2021

De-intensification and Intensification Treatments for High-Risk Prostate Cancer Patients Stratified by Genomic Risk (NRG-GU009)

Read more

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.